Targeted inhibitors: Efforts to optimize CDK4/CDK6 blockade (e.g., combination regimens or PROTACs), PI3K/AKT/mTOR inhibition (rapalogues in trials), BH3 mimetics such as venetoclax, and menin inhibitors for KMT2A-rearranged leukemias, several of which have shown promising clinical activity. This evidence concerns the gene CDK4 and leukemia.